PwC announced it will drop coverage of GLP‑1 weight‑loss drugs for U.S. employees unless they have diabetes, effective July. The decision hit staff during benefits renewal, sparking frustration. Employees argue the move ignores obesity’s link to workplace health and feels discriminatory.

Employees cite increased office hours and sedentary work as culprits behind weight gain, arguing that denying GLP‑1 access undermines productivity. A survey by the Peterson Center and KFF last year found 43 percent of large employers cover weight‑loss GLP‑1s, up from 28 percent in 2024, yet use remains higher than expected and associated health costs for employees.

PwC’s statement says it will continue covering GLP‑1s when prescribed for type 2 diabetes but exclude them from pharmacy benefits for weight management. The firm cites industry trends and the need to keep coverage sustainable, warning that unchecked drug spending could erode trust and strain employer‑sponsored plans and potentially limit future investment in employee wellness programs.

The move mirrors Blue Cross Blue Shield of Massachusetts, which also cut GLP‑1 coverage unless patients have diabetes, citing unsustainability. As weight‑loss drugs top the pharmaceutical sales chart, led by Eli Lilly and Novo Nordisk, employers face a dilemma: balancing cutting‑edge therapeutics with the cost pressures that threaten benefits budgets and compel strategic reassessment of healthcare spend across corporate sectors.